@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

# - resource -------------------------------------------------------------------

<http://hl7.org/fhir/CodeSystem/research-study-phase> a fhir:CodeSystem ;
  fhir:nodeRole fhir:treeRoot ;
  fhir:id [ fhir:v "research-study-phase"] ; # 
  fhir:meta [
     fhir:lastUpdated [ fhir:v "2025-10-04T10:33:12.998+11:00"^^xsd:dateTime ] ;
     fhir:profile ( [
       fhir:v "http://hl7.org/fhir/StructureDefinition/shareablecodesystem"^^xsd:anyURI ;
       fhir:link <http://hl7.org/fhir/StructureDefinition/shareablecodesystem>
     ] )
  ] ; # 
  fhir:text [
     fhir:status [ fhir:v "generated" ] ;
     fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n      <p class=\"res-header-id\">\n        <b>Generated Narrative: CodeSystem research-study-phase</b>\n      </p>\n      <a name=\"research-study-phase\"> </a>\n      <a name=\"hcresearch-study-phase\"> </a>\n      <div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\">\n        <p style=\"margin-bottom: 0px\">Last updated: 2022-05-15T16:55:11.085+11:00</p>\n        <p style=\"margin-bottom: 0px\">Profile: \n          <a href=\"shareablecodesystem.html\">Shareable CodeSystem</a>\n        </p>\n      </div>\n      <p>This case-sensitive code system \n        <code>http://hl7.org/fhir/research-study-phase</code> defines the following codes:\n      </p>\n      <table class=\"codes\">\n        <tr>\n          <td style=\"white-space:nowrap\">\n            <b>Code</b>\n          </td>\n          <td>\n            <b>Display</b>\n          </td>\n          <td>\n            <b>Definition</b>\n          </td>\n        </tr>\n        <tr>\n          <td style=\"white-space:nowrap\">n-a\n            <a name=\"research-study-phase-n-a\"> </a>\n          </td>\n          <td>N/A</td>\n          <td>Trials without phases (for example, studies of devices or behavioral interventions).</td>\n        </tr>\n        <tr>\n          <td style=\"white-space:nowrap\">early-phase-1\n            <a name=\"research-study-phase-early-phase-1\"> </a>\n          </td>\n          <td>Early Phase 1</td>\n          <td>Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0.</td>\n        </tr>\n        <tr>\n          <td style=\"white-space:nowrap\">phase-1\n            <a name=\"research-study-phase-phase-1\"> </a>\n          </td>\n          <td>Phase 1</td>\n          <td>Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.</td>\n        </tr>\n        <tr>\n          <td style=\"white-space:nowrap\">phase-1-phase-2\n            <a name=\"research-study-phase-phase-1-phase-2\"> </a>\n          </td>\n          <td>Phase 1/Phase 2</td>\n          <td>Trials that are a combination of phases 1 and 2.</td>\n        </tr>\n        <tr>\n          <td style=\"white-space:nowrap\">phase-2\n            <a name=\"research-study-phase-phase-2\"> </a>\n          </td>\n          <td>Phase 2</td>\n          <td>Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.</td>\n        </tr>\n        <tr>\n          <td style=\"white-space:nowrap\">phase-2-phase-3\n            <a name=\"research-study-phase-phase-2-phase-3\"> </a>\n          </td>\n          <td>Phase 2/Phase 3</td>\n          <td>Trials that are a combination of phases 2 and 3.</td>\n        </tr>\n        <tr>\n          <td style=\"white-space:nowrap\">phase-3\n            <a name=\"research-study-phase-phase-3\"> </a>\n          </td>\n          <td>Phase 3</td>\n          <td>Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.</td>\n        </tr>\n        <tr>\n          <td style=\"white-space:nowrap\">phase-4\n            <a name=\"research-study-phase-phase-4\"> </a>\n          </td>\n          <td>Phase 4</td>\n          <td>Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.</td>\n        </tr>\n      </table>\n    </div>"^^rdf:XMLLiteral ]
  ] ; # 
  fhir:extension ( [
     fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg"^^xsd:anyURI ] ;
     fhir:value [
       a fhir:Code ;
       fhir:v "brr"
     ]
  ] [
     fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/structuredefinition-standards-status"^^xsd:anyURI ] ;
     fhir:value [
       a fhir:Code ;
       fhir:v "trial-use"
     ]
  ] [
     fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/structuredefinition-fmm"^^xsd:anyURI ] ;
     fhir:value [
       a fhir:Integer ;
       fhir:v 0
     ]
  ] ) ; # 
  fhir:url [ fhir:v "http://hl7.org/fhir/research-study-phase"^^xsd:anyURI] ; # 
  fhir:version [ fhir:v "6.0.0-cibuild"] ; # 
  fhir:name [ fhir:v "ResearchStudyPhase"] ; # 
  fhir:title [ fhir:v "ResearchStudy Phase Code System"] ; # 
  fhir:status [ fhir:v "active"] ; # 
  fhir:experimental [ fhir:v false] ; # 
  fhir:date [ fhir:v "2022-05-15T16:55:11.085+11:00"^^xsd:dateTime] ; # 
  fhir:publisher [ fhir:v "HL7 (FHIR Project)"] ; # 
  fhir:contact ( [
     fhir:telecom ( [
       fhir:system [ fhir:v "url" ] ;
       fhir:value [ fhir:v "http://hl7.org/fhir" ]
     ] [
       fhir:system [ fhir:v "email" ] ;
       fhir:value [ fhir:v "fhir@lists.hl7.org" ]
     ] )
  ] ) ; # 
  fhir:description [ fhir:v "Codes for the stage in the progression of a therapy from initial experimental use in humans in clinical trials to post-market evaluation."] ; # 
  fhir:jurisdiction ( [
     fhir:coding ( [
       fhir:system [ fhir:v "http://unstats.un.org/unsd/methods/m49/m49.htm"^^xsd:anyURI ] ;
       fhir:code [ fhir:v "001" ] ;
       fhir:display [ fhir:v "World" ]
     ] )
  ] ) ; # 
  fhir:caseSensitive [ fhir:v true] ; # 
  fhir:valueSet [
     fhir:v "http://hl7.org/fhir/ValueSet/research-study-phase"^^xsd:anyURI ;
     fhir:link <http://hl7.org/fhir/ValueSet/research-study-phase>
  ] ; # 
  fhir:content [ fhir:v "complete"] ; # 
  fhir:concept ( [
     fhir:code [ fhir:v "n-a" ] ;
     fhir:display [ fhir:v "N/A" ] ;
     fhir:definition [ fhir:v "Trials without phases (for example, studies of devices or behavioral interventions)." ]
  ] [
     fhir:code [ fhir:v "early-phase-1" ] ;
     fhir:display [ fhir:v "Early Phase 1" ] ;
     fhir:definition [ fhir:v "Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0." ]
  ] [
     fhir:code [ fhir:v "phase-1" ] ;
     fhir:display [ fhir:v "Phase 1" ] ;
     fhir:definition [ fhir:v "Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients." ]
  ] [
     fhir:code [ fhir:v "phase-1-phase-2" ] ;
     fhir:display [ fhir:v "Phase 1/Phase 2" ] ;
     fhir:definition [ fhir:v "Trials that are a combination of phases 1 and 2." ]
  ] [
     fhir:code [ fhir:v "phase-2" ] ;
     fhir:display [ fhir:v "Phase 2" ] ;
     fhir:definition [ fhir:v "Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks." ]
  ] [
     fhir:code [ fhir:v "phase-2-phase-3" ] ;
     fhir:display [ fhir:v "Phase 2/Phase 3" ] ;
     fhir:definition [ fhir:v "Trials that are a combination of phases 2 and 3." ]
  ] [
     fhir:code [ fhir:v "phase-3" ] ;
     fhir:display [ fhir:v "Phase 3" ] ;
     fhir:definition [ fhir:v "Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug." ]
  ] [
     fhir:code [ fhir:v "phase-4" ] ;
     fhir:display [ fhir:v "Phase 4" ] ;
     fhir:definition [ fhir:v "Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use." ]
  ] ) . # 

# -------------------------------------------------------------------------------------

